Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...
facilitating the previously announced proposed merger with Kadimastem, which aims to create a combined Nasdaq-traded biotechnology company with product candidates in advanced stages of clinical development. Additionally, as previously announced,...
Cardurion Pharmaceuticals, Inc. a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as...
Spyre Therapeutics, Inc. a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of...
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an...
diseases. About Neurizon Therapeutics Limited: Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate,...
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova...
SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel...
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...
in the company's goal of delivering next-generation urology treatments. About Vensica Medical: Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a...
due to the potential for QT prolongation. About BioCryst Pharmaceuticals: BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases....
2nd International Conference on Biotechnology and Bioengineering, a Hybrid Event scheduled from October 24-25, 2024, Paris, France. We cordially invite competitors from all corners of the globe to showcase their expertise, talents, and research in...
NanoMedicine 2024 will cover the most recent international developments in the field of Nanobiotechnology and Nanomedicine. Participants will get a complete overview on the state of the art in these fields and on the research carried out and the...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...
With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start‐up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new...
Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by...
Biotech Congress 2024 (World Biotechnology and Bioengineering Congress) is an international conference organized by the Scholars Conferences scheduled during 23-24 September 2024 at Singapore. Biotech Congress 2024 (World Biotechnology and...
central locations for vaccination, reducing the risk of further infections. About Vaxxas: Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary...
Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Sergio Santillana, MD, MSc, MBA, as Chief Medical...
